New AVONEX(R) Dosing Innovations for People with Multiple Sclerosis Now Available in US - Marketwatch

WESTON, Mass., May 14, 2012 (BUSINESS WIRE) -- Biogen Idec (NASDAQ:BIIB) announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now ...

New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US - Yahoo Finance

Biogen Idec (NASDAQ: BIIB - News) announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies: The new ...

Biogen Idec announces availability of two new AVONEX dosing innovations for MS - News-Medical.Net

"One of the key aspects of treating MS is helping patients manage their treatment in order to get the most out of their therapy," said Peter B. Wade, M.D., medical director at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple ...

Avonex Pen and New Dose Titration Regimen Available - Monthly Prescribing Reference

The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in multiple sclerosis (MS), has been made available by Biogen Idec. Also, a new dose titration regimen, facilitated by the AVOSTARTGRIP ...

How High Can Biogen Idec Fly? - Motley Fool

Biogen Idec's success has everything to do with its focus on the multiple sclerosis and autoimmune landscape thanks to its key drugs Avonex, Rituxan, and Tysabri, as well as exciting new treatments waiting in the wings. Avonex, its best-selling ...

Biogen Idec Q1 revenues up 7 percent - Mass High Tech

Avonex (interferon beta-1a) revenues increased 3 percent year-over-year to $662 million, while worldwide unit demand for AVONEX decreased 4 percent year-over-year due to what the company called “unfavorable distribution channel dynamics.”

FDA Warns Of Potential Dangers Of Controversial Multiple Sclerosis Treatment - RTT News

Injectables like Teva's Copaxone, Biogen Idec's Avonex and Tysabri, and Merck Serono's Rebif and oral drug Gilenya, developed by Novartis AG, are some of the approved treatments for multiple sclerosis.

MS blog follow-up: immune-modulating therapies - Patriot-News Blogs

Now, here's where it becomes evident that I've never taken an immunology class. But I'll do my best: • Inferons: primarily treat RRMS (Avonex, Betaseron, Extavia, Rebif). Basically, interferons are proteins released in response to pathogens ...